Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers

Abstract

Mutations involving CTNNB1, the gene encoding beta-catenin, and other molecular alterations that affect the Wnt/beta-catenin signaling pathway are exceptionally common in hepatocellular carcinoma. Several of these alterations have also been associated with scarcity of immune cells in the tumor microenvironment and poor clinical response to immune checkpoint inhibitor therapy. In light of these associations, tumor biomarkers of beta-catenin status could have the potential to serve as clinical predictors of immunotherapy outcome. This editorial review article summarizes recent pre-clinical and clinical research pertaining to associations between beta-catenin activation and diminished anti-tumor immunity. Potential non-invasive biomarkers that may provide a window into this oncogenic mechanism of immune evasion are also presented and discussed.

Keywords

Hepatocellular carcinoma / immunotherapy / immune checkpoint / biomarkers / positron emission tomography / beta-catenin

References

[1] Altekruse SF,Reichman ME.Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005..J Clin Oncol2009;27:1485-91 PMCID:PMC2668555

[2] Yarchoan M,Villanueva A.Recent developments and therapeutic strategies against hepatocellular carcinoma..Cancer Res2019;79:4326-30

[3] El-khoueiry AB,Yau T.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502 PMCID:PMC7539326

[4] Zhu AX,Edeline J.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial..Lancet Oncol2018;19:940-52

[5] Finn RS,Ikeda M.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma..N Engl J Med2020;382:1894-905

[6] Finn RS,Merle P.Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)..JCO2019;37:4004

[7] Lee PC,Chen MH.Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma..Cancers (Basel)2020;12:182 PMCID:PMC7017111

[8] Ang C,Ali SM.Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma..Oncotarget2019;10:4018-25 PMCID:PMC6592287

[9] Finn RS,Merle P.Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial..J Clin Oncol2020;38:193-202

[10] Shimada S,Akiyama Y.Comprehensive molecular and immunological characterization of hepatocellular carcinoma..EBioMedicine2019;40:457-70 PMCID:PMC6412165

[11] Pinyol R,Llovet JM.Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC..Clin Cancer Res2019;25:2021-3 PMCID:PMC6445700

[12] Luke JJ,Sweis RF,Gajewski TF.WNT/β-catenin pathway activation correlates with immune exclusion across human cancers..Clin Cancer Res2019;25:3074-83 PMCID:PMC6522301

[13] Spranger S,Gajewski TF.Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity..Nature2015;523:231-5

[14] Taube JM,McMiller TL.Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade..Clin Cancer Res2015;21:3969-76 PMCID:PMC4558237

[15] Ayers M,Nebozhyn M.IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade..J Clin Invest2017;127:2930-40 PMCID:PMC5531419

[16] Harding JJ,Armenia J.Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies..Clin Cancer Res2019;25:2116-26 PMCID:PMC6689131

[17] Spranger S.Impact of oncogenic pathways on evasion of antitumour immune responses..Nat Rev Cancer2018;18:139-47 PMCID:PMC6685071

[18] Ou Q,Li A.Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma..Ann Transl Med2020;8:230 PMCID:PMC7154492

[19] Yaguchi T,Kido K.Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells..J Immunol2012;189:2110-7

[20] Spranger S,Horton B.Tumor-residing Batf3 dendritic cells are required for effector T Cell trafficking and adoptive T cell therapy..Cancer Cell2017;31:711-23.e4 PMCID:PMC5650691

[21] Spranger S.A new paradigm for tumor immune escape: β-catenin-driven immune exclusion..J Immunother Cancer2015;3:43 PMCID:PMC4570721

[22] Ruiz de Galarreta M,Molina-Sánchez P.β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma..Cancer Discov2019;9:1124-41 PMCID:PMC6677618

[23] Calderaro J,Imbeaud S.Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification..J Hepatol2017;67:727-38

[24] Clevers H.Wnt/beta-catenin signaling in development and disease..Cell2006;127:469-80

[25] Audard V,Elie C.Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations..J Pathol2007;212:345-52

[26] Nishida N,Nagasaka T,Goel A.Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis..Cancer Res2007;67:4586-94

[27] Kim G,Djordjevic B.Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association..Mod Pathol2018;31:1553-9 PMCID:PMC6168348

[28] Gougelet A,Senni N.Hepatocellular carcinomas with mutational activation of beta-catenin require choline and can be detected by positron emission tomography..Gastroenterology2019;157:807-22

[29] Senni N,Cabrerizo Granados D.β-catenin-activated hepatocellular carcinomas are addicted to fatty acids..Gut2019;68:322-34

[30] Hart MJ,Albert IN,Polakis P.Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3β..Current Biology1998;8:573-81

[31] He X,Tamai K.LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way..Development2004;131:1663-77

[32] van de Wetering M,Dooijes D.Armadillo coactivates transcription driven by the product of the drosophila segment polarity gene dTCF..Cell1997;88:789-99

[33] Zucman-Rossi J,Nault JC.Genetic landscape and biomarkers of hepatocellular carcinoma..Gastroenterology2015;149:1226-39.e4

[34] Gao C,Broaddus R,Xue F.Exon 3 mutations of CTNNB1 drive tumorigenesis: a review..Oncotarget2018;9:5492-508 PMCID:PMC5797067

[35] Li W,Ma Z.Multi-omics analysis of microenvironment characteristics and immune escape mechanisms of hepatocellular carcinoma..Front Oncol2019;9:1019 PMCID:PMC6803502

[36] Schulze K,Letouzé E.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets..Nat Genet2015;47:505-11 PMCID:PMC4587544

[37] Khemlina G,Kurzrock R.The biology of hepatocellular carcinoma: implications for genomic and immune therapies..Mol Cancer2017;16:149 PMCID:PMC5577674

[38] Capurro M,Shi W.Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling..J Cell Sci2014;127:1565-75

[39] Li N,Liu X.A frizzled-like cysteine-rich domain in glypican-3 mediates wnt binding and regulates hepatocellular carcinoma tumor growth in mice..Hepatology2019;70:1231-45 PMCID:PMC6783318

[40] Wei Y,Prigent S,Tiollais P.Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features..Hepatology2002;36:692-701

[41] Finch PW,Kelley MJ.Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action..Proc Natl Acad Sci U S A1997;94:6770-5 PMCID:PMC21233

[42] Taniguchi K,Aderca IN.Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas..Oncogene2002;21:4863-71

[43] Ding Y,Lino AC,Lafaille JJ.Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells..Nat Med2008;14:162-9

[44] Saegusa M,Yoshida T.beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis..Br J Cancer2001;84:209-17 PMCID:PMC2363713

[45] Galluzzi L,Fuchs E.WNT signaling in cancer immunosurveillance..Trends Cell Biol2019;29:44-65 PMCID:PMC7001864

[46] Fujita M,Hasegawa T.Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations..EBioMedicine2020;53:102659 PMCID:PMC7048625

[47] Guichard C,Imbeaud S.Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma..Nat Genet2012;44:694-8 PMCID:PMC3819251

[48] Fan X,Li Y.Genetic and epigenetic regulation of E-cadherin signaling in human hepatocellular carcinoma..Cancer Manag Res2019;11:8947-63 PMCID:PMC6801489

[49] Li L,Wen Z.Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma..Oncol Lett2020;19:2739-48 PMCID:PMC7068659

[50] Lehwald N,Jang KY.β-catenin regulates hepatic mitochondrial function and energy balance in mice..Gastroenterology2012;143:754-64

[51] Kolthammer JA,Tenley N.PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline..Eur J Nucl Med Mol Imaging2011;38:1248-56

[52] Kwee SA,Kuang Y.[18F]Fluorocholine PET/CT imaging of liver cancer: radiopathologic correlation with tissue phospholipid profiling..Mol Imaging Biol2017;19:446-55 PMCID:PMC5407951

[53] Colnot S,Niwa-Kawakita M.Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas..Proc Natl Acad Sci U S A2004;101:17216-21 PMCID:PMC535370

[54] Kwee SA,Sato MM.Transcriptomics associates molecular features with ¹⁸F-fluorocholine PET/CT imaging phenotype and its potential relationship to survival in hepatocellular carcinoma..Cancer Res2019;79:1696-704 PMCID:PMC6494445

[55] Jaiswal S.Clonal hematopoiesis in human aging and disease..Science2019;366:eaan4673

[56] Razavi P,Brown DN.High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants..Nat Med2019;25:1928-37 PMCID:PMC7061455

[57] Buscarlet M,Zada YF.DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions..Blood2017;130:753-62

[58] Loberg MA,Goodwin LO.Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis..Leukemia2019;33:1635-49 PMCID:PMC6609470

[59] Patra KC,Mizukami Y.Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism..Nat Cell Biol2018;20:811-22 PMCID:PMC6044476

[60] Nomura R,Mitomi H.GNAS mutation as an alternative mechanism of activation of the Wnt/β-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type..Hum Pathol2014;45:2488-96

[61] Romero D,Vary CP.Functional blockade of Smad4 leads to a decrease in beta-catenin levels and signaling activity in human pancreatic carcinoma cells..Carcinogenesis2008;29:1070-6

[62] Hoshida Y,Kobayashi M.Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma..Cancer Res2009;69:7385-92 PMCID:PMC3549578

[63] Boyault S,de Reyniès A.Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets..Hepatology2007;45:42-52

[64] Chiang DY,Hoshida Y.Focal gains of VEGFA and molecular classification of hepatocellular carcinoma..Cancer Res2008;68:6779-88 PMCID:PMC2587454

[65] Huang X,Wang J,Xiong H.Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications..Aging (Albany NY)2020;12:4970-95 PMCID:PMC7138576

[66] Li T,Wang B.TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells..Cancer Res2017;77:e108-10 PMCID:PMC6042652

[67] Tan PS,Goossens N.Clinicopathological indices to predict hepatocellular carcinoma molecular classification..Liver Int2016;36:108-18 PMCID:PMC4674393

[68] Qiu J,Zhang K.Refining cancer management using integrated liquid biopsy..Theranostics2020;10:2374-84 PMCID:PMC7019147

[69] Huang da W,Lempicki RA.Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources..Nat Protoc2009;4:44-57

[70] Ramapriyan R,Barsoumian HB.Altered cancer metabolism in mechanisms of immunotherapy resistance..Pharmacol Ther2019;195:162-71

[71] Wei R,Wang X.Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning..EBioMedicine2018;35:124-32

[72] Wang T,Tang H.Integrated nomograms to predict overall survival and recurrence-free survival in patients with combined hepatocellular cholangiocarcinoma (cHCC) after liver resection..Aging (Albany NY)2020;12:15334-58 PMCID:PMC7467372

[73] Chen W,Gallas BD,Sahiner B.On the assessment of the added value of new predictive biomarkers..BMC Med Res Methodol2013;13:98 PMCID:PMC3733611

[74] Cook NR.Quantifying the added value of new biomarkers: how and how not..Diagn Progn Res2018;2:14 PMCID:PMC6460632

[75] Benson AB,Abbott DE.Guidelines insights: hepatobiliary cancers, Version 2.2019..J Natl Compr Canc Netw2019;17:302-10